Home>
US Stocks>
Arbutus Biopharma Corporation

Arbutus Biopharma Corporation share price today

(ABUS)

Arbutus Biopharma Corporation share price is $3.68 & ₹311.66 as on 7 Dec 2024, 2.30 'hrs' IST

$3.68

▲

0.05

(1.38%)

Market is closed - opens 8 PM, 09 Dec 2024

View live Arbutus Biopharma Corporation share price in Dollar and Rupees. Guide to invest in Arbutus Biopharma Corporation from India. Also see the sentimental analysis on Indian investors investing in Arbutus Biopharma Corporation. Get details on the Indian mutual funds that are investing in Arbutus Biopharma Corporation. Get Analyst recommendations and forecasts along with all the Arbutus Biopharma Corporation's financials.

Arbutus Biopharma Corporation share price movements

$3.61
$3.73
$3.68
2.04%
Downside
Day's Volatility :3.22%
Upside
1.21%
$1.98
$4.73
$3.68
46.2%
Downside
52 Weeks Volatility :58.1%
Upside
22.12%

Arbutus Biopharma Corporation Returns

Period	Arbutus Biopharma Corporation	Sector (Health Care)	Index (Russel 2000)
3 Months	-19.15%	-5.7%	0.0%
6 Months	15.61%	-0.9%	0.0%
1 Year	77.07%	9.9%	0.0%
3 Years	-15.78%	8.4%	-22.1%

Arbutus Biopharma Corporation Key Statistics

in dollars & INR

Previous Close	$3.63
Open	$3.59
Today's High	$3.725
Today's Low	$3.605
Market Capitalization	$708.7M
Today's Volume	$779.6K
52 Week High	$4.725
52 Week Low	$1.98
Revenue TTM	$6.7M
EBITDA	$-77.1M
Earnings Per Share (EPS)	$-0.47
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-67.81%

How to invest in Arbutus Biopharma Corporation from India?

It is very easy for Indian residents to invest directly in Arbutus Biopharma Corporation from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Arbutus Biopharma Corporation stock in both rupees (INR) and dollars (USD). Search for Arbutus Biopharma Corporation or ABUS on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Arbutus Biopharma Corporation or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Arbutus Biopharma Corporation shares which would translate to 0.230 fractional shares of Arbutus Biopharma Corporation as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Arbutus Biopharma Corporation

25%

Period: Sep 8, 2024 to Dec 7, 2024. Change in 30 Days versus previous period

Search volume for Arbutus Biopharma Corporation on INDmoney from India has grown in the last 30 days as on Dec 8, 2024. 25% more investors are searching Arbutus Biopharma Corporation in the last 30 days versus the previous period.

Global Institutional Holdings in Arbutus Biopharma Corporation

Morgan Stanley - Brokerage Accounts
11.46%
Whitefort Capital Management, LP.
6.79%
BlackRock Inc
6.10%
Vanguard Group Inc
4.71%
Two Seas Capital LP
4.43%
State Street Corp
2.33%

Analyst Recommendation on Arbutus Biopharma Corporation

Buy

81%Buy

18%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Arbutus Biopharma Corporation(by analysts ranked 0 to 5 stars)

Based on 11 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Arbutus Biopharma Corporation

What analysts predicted

Upside of 97.95%

Current:

$3.68

Target:

$7.28

Insights on Arbutus Biopharma Corporation

Decreasing Revenue
Revenue is down for the last 2 quarters, 1.72M → 1.33M (in $), with an average decrease of 22.4% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -19.79M → -19.71M (in $), with an average increase of 0.4% per quarter
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 42.3% return, outperforming this stock by 54.6%

Arbutus Biopharma Corporation Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$5.9M	↓ 44.86%
Net Income	$-57.1M	↓ 32.35%
Net Profit Margin	-967.8%	↓ 179.01%

	FY19	Y/Y Change
Revenue	$6.0M	↑ 1.88%
Net Income	$-153.7M	↑ 169.22%
Net Profit Margin	-2.6K%	↓ 1589.56%

	FY20	Y/Y Change
Revenue	$6.9M	↑ 15.02%
Net Income	$-65.2M	↓ 57.58%
Net Profit Margin	-943.17%	↑ 1614.19%

	FY21	Y/Y Change
Revenue	$11.0M	↑ 58.92%
Net Income	$-77.4M	↑ 18.62%
Net Profit Margin	-703.96%	↑ 239.21%

	FY22	Y/Y Change
Revenue	$39.0M	↑ 255.11%
Net Income	$-69.5M	↓ 10.21%
Net Profit Margin	-178.01%	↑ 525.95%

	FY23	Y/Y Change
Revenue	$18.1M	↓ 53.51%
Net Income	$-72.8M	↑ 4.89%
Net Profit Margin	-401.57%	↓ 223.56%

	Q2 FY23	Q/Q Change
Revenue	$4.7M	↓ 30.45%
Net Income	$-17.1M	↑ 10.55%
Net Profit Margin	-367.53%	↓ 136.29%

	Q3 FY23	Q/Q Change
Revenue	$4.7M	↑ 0.15%
Net Income	$-20.1M	↑ 17.61%
Net Profit Margin	-431.6%	↓ 64.07%

	Q4 FY23	Q/Q Change
Revenue	$2.1M	↓ 53.95%
Net Income	$-19.3M	↓ 3.94%
Net Profit Margin	-900.33%	↓ 468.73%

	Q1 FY24	Q/Q Change
Revenue	$1.5M	↓ 28.58%
Net Income	$-17.9M	↓ 7.44%
Net Profit Margin	-1.2K%	↓ 266.45%

	Q2 FY24	Q/Q Change
Revenue	$1.7M	↑ 12.66%
Net Income	$-19.8M	↑ 10.75%
Net Profit Margin	-1.1K%	↑ 19.85%

	Q3 FY24	Q/Q Change
Revenue	$1.3M	↓ 22.42%
Net Income	$-19.7M	↓ 0.4%
Net Profit Margin	-1.5K%	↓ 325.59%

	FY18	Y/Y Change
Total Assets	$227.9M	↓ 3.92%
Total Liabilities	$27.7M	↓ 49.36%

	FY19	Y/Y Change
Total Assets	$105.5M	↓ 53.69%
Total Liabilities	$32.8M	↑ 18.38%

	FY20	Y/Y Change
Total Assets	$137.1M	↑ 29.89%
Total Liabilities	$35.1M	↑ 7.08%

	FY21	Y/Y Change
Total Assets	$204.5M	↑ 49.17%
Total Liabilities	$35.0M	↓ 0.19%

	FY22	Y/Y Change
Total Assets	$195.4M	↓ 4.43%
Total Liabilities	$58.6M	↑ 67.11%

	FY23	Y/Y Change
Total Assets	$144.4M	↓ 26.11%
Total Liabilities	$38.4M	↓ 34.46%

	Q2 FY23	Q/Q Change
Total Assets	$176.8M	↓ 7.53%
Total Liabilities	$42.1M	↓ 10.95%

	Q3 FY23	Q/Q Change
Total Assets	$158.6M	↓ 10.28%
Total Liabilities	$39.3M	↓ 6.71%

	Q4 FY23	Q/Q Change
Total Assets	$144.4M	↓ 8.98%
Total Liabilities	$38.4M	↓ 2.34%

	Q1 FY24	Q/Q Change
Total Assets	$150.3M	↑ 4.08%
Total Liabilities	$35.7M	↓ 7.11%

	Q2 FY24	Q/Q Change
Total Assets	$160.0M	↑ 6.49%
Total Liabilities	$37.6M	↑ 5.43%

	Q3 FY24	Q/Q Change
Total Assets	$140.4M	↓ 12.25%
Total Liabilities	$33.6M	↓ 10.74%

	FY18	Y/Y Change
Operating Cash Flow	$-67.9M	↑ 39.71%
Investing Cash Flow	$-4.1M	↓ 114.83%
Financing Cash Flow	$55.6M	↑ 12.78%

	FY19	Y/Y Change
Operating Cash Flow	$-71.0M	↑ 4.57%
Investing Cash Flow	$28.3M	↓ 786.65%
Financing Cash Flow	$37.5M	↓ 32.63%

	FY20	Y/Y Change
Operating Cash Flow	$-51.4M	↓ 27.55%
Investing Cash Flow	$-14.9M	↓ 152.61%
Financing Cash Flow	$86.7M	↑ 131.59%

	FY21	Y/Y Change
Operating Cash Flow	$-67.5M	↑ 31.28%
Investing Cash Flow	$-12.7M	↓ 14.96%
Financing Cash Flow	$137.2M	↑ 58.2%

	FY22	Y/Y Change
Operating Cash Flow	$-35.4M	↓ 47.65%
Investing Cash Flow	$-74.9M	↑ 491.12%
Financing Cash Flow	$31.8M	↓ 76.82%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-19.6M	↓ 28.36%
Investing Cash Flow	$1.4M	↓ 91.36%
Financing Cash Flow	$4.7M	↓ 76.77%

Arbutus Biopharma Corporation Technicals Summary

Sell

Neutral

Buy

Arbutus Biopharma Corporation is currently in a neutral trading position according to technical analysis indicators.

Arbutus Biopharma Corporation Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Arbutus Biopharma Corporation	-3.2%	15.61%	77.07%	-15.78%	54.47%
Regeneron Pharmaceuticals, Inc.	-7.31%	-23.34%	-9.49%	15.35%	108.86%
Biontech Se	7.41%	21.29%	18.26%	-58.19%	324.43%
Alnylam Pharmaceuticals, Inc.	-9.23%	64.08%	47.33%	46.0%	106.67%
Vertex Pharmaceuticals Incorporated	-11.0%	-4.83%	29.09%	120.68%	108.8%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Arbutus Biopharma Corporation	NA	NA	0.0	-0.54	-0.68	-0.33	NA	0.56
Regeneron Pharmaceuticals, Inc.	18.56	18.56	1.12	44.92	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.21	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Arbutus Biopharma Corporation	Buy	$708.7M	54.47%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$82.9B	108.86%	18.56	33.61%
Biontech Se	Buy	$28.5B	324.43%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	106.67%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$118.4B	108.8%	32.84	-4.51%

About Arbutus Biopharma Corporation

arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the hbv treatment landscape and cure hepatitis b virus disease. in addition to our hbv assets, we are developing a pipeline of programs that leverage our expertise in rna interference (rnai) therapeutics and our lipid nanoparticle (lnp) technology.

Organization	Arbutus Biopharma Corporation
Employees	73
CEO	Mr. Michael J. McElhaugh
Industry	Health Technology

Management People of Arbutus Biopharma Corporation

Name	Title
Mr. Michael J. McElhaugh	Co-Founder, Interim President, CEO & Director
Dr. Michael J. Sofia Ph.D.	Chief Scientific Officer
Mr. David C. Hastings CPA	CFO & Chief Accounting Officer
Ms. Lisa M. Caperelli	Vice President of Investor Relations
Mr. J. Christopher Naftzger BA, Esq., J.D.	General Counsel, Chief Compliance Officer & Secretary
Ms. Shannon Briscoe SPHR	Vice President of Human Resources
Dr. Karen Sims M.D., Ph.D.	Chief Medical Officer
Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.	Corporate Secretary

Important FAQs about investing in Arbutus Biopharma Corporation from India :

What is Arbutus Biopharma Corporation share price today?

Arbutus Biopharma Corporation (ABUS) share price today is $3.68.

Can Indians buy Arbutus Biopharma Corporation shares?

Yes, Indians can invest in the Arbutus Biopharma Corporation (ABUS) from India.

With INDmoney, you can buy Arbutus Biopharma Corporation at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Arbutus Biopharma Corporation at zero transaction cost.

How can I buy Arbutus Biopharma Corporation shares from India?

It is very easy to buy Arbutus Biopharma Corporation from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Arbutus Biopharma Corporation be purchased?

Yes, you can buy fractional shares of Arbutus Biopharma Corporation with INDmoney app.

What are the documents required to start investing in Arbutus Biopharma Corporation stocks?

To start investing in Arbutus Biopharma Corporation, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.